Literature DB >> 6508987

The protein binding of timegadine determined by equilibrium dialysis.

S George, A McBurney, J Ward.   

Abstract

The protein binding of timegadine to albumin, serum, plasma and plasma enriched with the acute phase reactants alpha 1-acid glycoprotein, alpha 1-anti-trypsin and C-reactive protein was determined by equilibrium dialysis. The effects of other analgesic and anti-inflammatories (indomethacin, ketoprofen, paracetamol and sodium salicylate) and other basic drugs (disopyramide, lignocaine, propranolol and quinidine) on the binding of timegadine were also determined. Timegadine binding was concentration-dependent up to 0.5 micrograms/ml, but independent above this level up to 10.0 micrograms/ml, the mean and standard error being 93.8 +/- 0.5%. Albumin accounted for only 32.4% of timegadine bound to plasma. Plasma enrichment with the acute phase reactants led to significant increases in timegadine binding. Simultaneous dialysis with other drugs caused significant decreases in timegadine binding.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508987      PMCID: PMC1463545          DOI: 10.1111/j.1365-2125.1984.tb02543.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

Review 1.  Binding of drugs to serum albumin (first of two parts).

Authors:  J Koch-Weser; E M Sellers
Journal:  N Engl J Med       Date:  1976-02-05       Impact factor: 91.245

2.  A new antiinflammatory compound, timegadine (N-cyclohexyl-N"-4-[2-methylquinolyl]-N'-2-thiazolylguanidine), which inhibits both prostaglandin and 12-hydroxyeicosatetraenoic acid (12-HETE) formation.

Authors:  I Ahnfelt-Rønne; E Arrigoni-Martelli
Journal:  Biochem Pharmacol       Date:  1980-12       Impact factor: 5.858

3.  Intravenous propranolol in patients with inflammation.

Authors:  D G Waller; C L Smith; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

4.  On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction.

Authors:  A Barchowsky; D G Shand; W W Stargel; G S Wagner; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

Review 5.  Antirheumatic drugs: clinical pharmacology and therapeutic use.

Authors:  G L Craig; W W Buchanan
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

6.  Clinical Pharmacokinetics of indomethacin.

Authors:  L Helleberg
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

7.  C-reactive protein fifty years on.

Authors:  M B Pepys
Journal:  Lancet       Date:  1981-03-21       Impact factor: 79.321

8.  Concentration dependent plasma protein binding of salicylate in rheumatoid patients.

Authors:  R Ekstrand; G Alvan; O Borga
Journal:  Clin Pharmacokinet       Date:  1979 Mar-Apr       Impact factor: 6.447

9.  Drug binding in sera deficient in lipoproteins, albumin or orosomucoid.

Authors:  E Pike; P Kierulf; B Skuterud; J E Bredesen; P K Lunde
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

10.  Alpha1-acid glycoprotein concentration and protein binding in trauma.

Authors:  D J Edwards; D Lalka; F Cerra; R L Slaughter
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

View more
  2 in total

1.  The plasma protein binding of basic drugs.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

2.  The pharmacokinetics of timegadine and two of its metabolites after multiple oral dosing, and the effects of concomitant administration of ibuprofen.

Authors:  S George; A McBurney; J W Ward
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.